These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33799933)

  • 1. Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis.
    Szudy-Szczyrek A; Bachanek-Mitura O; Gromek T; Chromik K; Mital A; Szczyrek M; Krupski W; Szumiło J; Kanduła Z; Helbig G; Hus M
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33799933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
    Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
    Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
    Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
    N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
    DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
    Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
    Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
    J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
    Lübke J; Schwaab J; Naumann N; Horny HP; Weiß C; Metzgeroth G; Kreil S; Cross NCP; Sotlar K; Fabarius A; Hofmann WK; Valent P; Gotlib J; Jawhar M; Reiter A
    J Clin Oncol; 2022 Jun; 40(16):1783-1794. PubMed ID: 35235417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
    Gotlib J; Kluin-Nelemans HC; Akin C; Hartmann K; Valent P; Reiter A
    Expert Opin Biol Ther; 2021 Apr; 21(4):487-498. PubMed ID: 33063554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of midostaurin in advanced systemic mastocytosis.
    Chandesris MO; Damaj G; Lortholary O; Hermine O
    Blood Lymphat Cancer; 2017; 7():25-35. PubMed ID: 31360083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
    Tashi T; Deininger MW
    Immunol Allergy Clin North Am; 2023 Nov; 43(4):723-741. PubMed ID: 37758409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
    Jawhar M; Schwaab J; Meggendorfer M; Naumann N; Horny HP; Sotlar K; Haferlach T; Schmitt K; Fabarius A; Valent P; Hofmann WK; Cross NCP; Metzgeroth G; Reiter A
    Haematologica; 2017 Jun; 102(6):1035-1043. PubMed ID: 28255023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level.
    Liu MK; Liu F; Dai YT; Weng XQ; Cheng LL; Fan LQ; Liu H; Jiang L; Sun XJ; Fang H; Wang L; Zhao WL
    Front Immunol; 2023; 14():1210909. PubMed ID: 37638009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
    Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
    Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rare Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease That Transformed to Acute Leukemia With
    Liman AD; Shields J; Liman AK
    J Med Cases; 2020 Oct; 11(10):317-319. PubMed ID: 34434337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.